Momenta Pharmaceuticals - MNTA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$52.48
+0 (0.00%)
Get New Momenta Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MNTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MNTA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Momenta Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $52.48.

This chart shows the closing price for MNTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Momenta Pharmaceuticals. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/25/2020HC WainwrightDowngradeBuy ➝ Neutral$52.50Low
8/24/2020Raymond JamesInitiated CoverageMarket PerformLow
8/20/2020Truist FinancialDowngradeBuy ➝ Hold$53.00Low
8/20/2020Stifel NicolausBoost TargetBuy ➝ Hold$47.00 ➝ $52.50Low
8/20/2020Cantor FitzgeraldBoost TargetNeutral$38.00 ➝ $52.50Low
8/19/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$48.00 ➝ $52.50High
8/11/2020HC WainwrightReiterated RatingBuy$50.00High
8/3/2020CowenUpgradeMarket Perform ➝ OutperformHigh
7/29/2020Piper SandlerReiterated RatingBuy$45.00Low
7/29/2020HC WainwrightBoost TargetBuy$46.00 ➝ $50.00High
6/24/2020Stifel NicolausReiterated RatingBuyMedium
6/18/2020SunTrust BanksUpgradeBuyHigh
6/17/2020SunTrust BanksBoost Target$50.00 ➝ $57.00High
6/16/2020JPMorgan Chase & Co.Boost TargetOverweight$37.00 ➝ $42.00Low
6/16/2020HC WainwrightReiterated RatingBuy$40.00 ➝ $46.00High
6/16/2020Cantor FitzgeraldBoost TargetPositive ➝ Neutral$30.00 ➝ $38.00High
6/15/2020Stifel NicolausReiterated RatingBuy$47.00Medium
6/15/2020Piper SandlerReiterated RatingBuy$45.00Medium
6/15/2020Wells Fargo & CompanyBoost TargetOverweight$40.00 ➝ $48.00High
5/26/2020Stifel NicolausReiterated RatingBuyHigh
5/8/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $40.00Medium
5/7/2020Stifel NicolausReiterated RatingBuy$46.00Low
4/7/2020Stifel NicolausReiterated RatingBuyHigh
3/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$29.00High
2/26/2020Cantor FitzgeraldReiterated RatingNeutral$22.00 ➝ $30.00Medium
2/5/2020Piper SandlerBoost Target$35.00 ➝ $45.00Low
2/4/2020HC WainwrightBoost TargetBuy$24.00 ➝ $36.00High
1/27/2020Stifel NicolausReiterated RatingPositive ➝ Buy$29.00 ➝ $43.00High
1/15/2020SunTrust BanksBoost TargetBuy$50.00High
1/14/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$14.00 ➝ $30.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$29.00High
11/6/2019Wells Fargo & CompanyInitiated CoverageOutperformHigh
10/24/2019Stifel NicolausReiterated RatingBuy$29.00High
9/25/2019HC WainwrightInitiated CoverageBuy$24.00High
9/17/2019Piper Jaffray CompaniesSet TargetBuy$35.00Low
5/2/2019Cantor FitzgeraldSet TargetHold$16.00Medium
3/18/2019BTIG ResearchInitiated CoverageNeutral$14.15High
2/22/2019Stifel NicolausReiterated RatingBuy$29.00Low
2/22/2019Cantor FitzgeraldReiterated RatingHold$16.00High
1/8/2019Stifel NicolausReiterated RatingBuyHigh
1/4/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
11/7/2018Stifel NicolausSet TargetBuy$39.00Low
11/7/2018Cantor FitzgeraldSet TargetHold$16.00High
11/5/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$35.00Medium
10/10/2018Cantor FitzgeraldSet TargetHold$24.00Medium
10/10/2018Stifel NicolausReiterated RatingBuy$40.00Medium
10/1/2018Cantor FitzgeraldSet TargetHold$24.00High
8/9/2018Cantor FitzgeraldSet TargetHold$24.00High
6/14/2018Cantor FitzgeraldReiterated RatingNeutralMedium
6/11/2018Cantor FitzgeraldInitiated CoverageHold$24.00High
2/22/2018Stifel NicolausUpgradeHold ➝ Buy$18.00 ➝ $21.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Momenta Pharmaceuticals logo
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $52.48
Low: $52.48
High: $52.48

50 Day Range

MA: $52.44
Low: $52.26
High: $52.49

52 Week Range

Now: $52.48
Low: $12.21
High: $52.53

Volume

N/A

Average Volume

1,939,894 shs

Market Capitalization

$6.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Momenta Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Momenta Pharmaceuticals in the last year:
View the latest analyst ratings for MNTA.

What is the current price target for Momenta Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Momenta Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Momenta Pharmaceuticals in the next year.
View the latest price targets for MNTA.

What is the current consensus analyst rating for Momenta Pharmaceuticals?

Momenta Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MNTA.

What other companies compete with Momenta Pharmaceuticals?

How do I contact Momenta Pharmaceuticals' investor relations team?

Momenta Pharmaceuticals' physical mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is 617-491-9700 and its investor relations email address is [email protected] The official website for Momenta Pharmaceuticals is www.momentapharma.com. Learn More about contacing Momenta Pharmaceuticals investor relations.